首页> 外文期刊>Nature Communications >Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy
【24h】

Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy

机译:患者来源的原代细胞的纵向单细胞RNA测序揭示了药物诱导的干细胞等级不忠

获取原文
           

摘要

Chemo-resistance is one of the major causes of cancer-related deaths. Here we used single-cell transcriptomics to investigate divergent modes of chemo-resistance in tumor cells. We observed that higher degree of phenotypic intra-tumor heterogeneity (ITH) favors selection of pre-existing drug-resistant cells, whereas phenotypically homogeneous cells engage covert epigenetic mechanisms to trans-differentiate under drug-selection. This adaptation was driven by selection-induced gain of H3K27ac marks on bivalently poised resistance-associated chromatin, and therefore not expressed in the treatment-na?ve setting. Mechanistic interrogation of this phenomenon revealed that drug-induced adaptation was acquired upon the loss of stem factor SOX2, and a concomitant gain of SOX9. Strikingly we observed an enrichment of SOX9 at drug-induced H3K27ac sites, suggesting that tumor evolution could be driven by stem cell-switch-mediated epigenetic plasticity. Importantly, JQ1 mediated inhibition of BRD4 could reverse drug-induced adaptation. These results provide mechanistic insights into the modes of therapy-induced cellular plasticity and underscore the use of epigenetic inhibitors in targeting tumor evolution.
机译:耐化学性是与癌症相关的死亡的主要原因之一。在这里,我们使用单细胞转录组学来研究肿瘤细胞中化学耐药性的不同模式。我们观察到较高的表型肿瘤内异质性(ITH)有利于选择预先存在的耐药细胞,而表型同质细胞则参与隐蔽表观遗传机制以在药物选择下进行转分化。这种适应性是由选择诱导的三价平衡抗性相关染色质上的H3K27ac标记获得的增益驱动的,因此未在初次治疗的环境中表达。对这种现象的机械询问表明,药物诱导的适应性是在失去干因子SOX2后获得的,并伴随有SOX9的获得。令人惊讶地,我们在药物诱导的H3K27ac位点观察到SOX9的富集,表明肿瘤的进化可能是由干细胞开关介导的表观遗传可塑性驱动的。重要的是,JQ1介导的BRD4抑制作用可以逆转药物诱导的适应。这些结果为治疗诱导的细胞可塑性的模式提供了机械方面的见解,并强调了表观遗传抑制剂在靶向肿瘤发展中的应用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号